Cell entry mechanisms of SARS-CoV2. Fusion peptide molecules in the spike protein need to undergo a conformational change ("bending") to help "clip" the 2 membranes together (virus & human cell);energy is needed to overcome a repulsive hydration force. 1/n
pnas.org/content/117/21…
The fusion process - or final conformational change- varies by availability of multiple cellular proteases, and may be facilitated by environmental factors (physical force/temperature/chemical) in addition to furin preactivation.

2/n
The SARS-CoV-2 virus is a 'more advanced model' than the original 2003 SARS virus, in that its RBD remains hidden (in lying down / 'off' position) helping it escape our immune surveillance.

While this might theoretically affect its ability to bind to the ACE-2 receptor,

3/6
it makes up for this 'hidden' status by greater affinity to the ACE-2 receptor. Thus, in sum, its ACE-2 binding ability is comparable to the 2003 virus. Viruses are known to conceal critical parts of their body by keeping them out of sight in crevices by folding of proteins.
4/6
Not all parts of the virus are 'attractive' targets for our immune system. In the case of the SARS-CoV-2 virus, the RBD of its spike protein is considered to be one of the most critical immune targets. That is why most vaccines target the spike protein.

5/6
Although we often hear simplistically about 'virus spike protein binding to our ACE-2 receptor', there are so many processes that influence viral entry. Understanding each one of these physical, chemical& biological elements will help solve many mysteries about the pandemic.

6/6

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Rajeev Jayadevan

Rajeev Jayadevan Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @RajeevJayadevan

4 May
This thread is a classic example of personal bias overriding scientific temperament. >80% COVID-19 patients recover with no medication, but credit is given to drug given.

Bacteria, their benefits apart, do not require to be killed, unless they cause secondary infection.

🧵 1/4
Besides no one gives any journal the license to make guidelines. Peer reviewed journals hold a high standard of eliminating fraudulent claims and at this time, they are a relatively credible source of evidence. Whether we adapt from the paper depends on many factors.

2/3
For starters, never believe the conclusions of any research paper. As a doctor you must have the basic knowledge of biostatistics to look at the methodology, raw data, primary outcomes, confidence intervals and the merits of the tests of association they used.

3/3
Read 5 tweets
4 May
The dubiously named “double mutant” has become “single” it seems.

Yes, the B.1.617 has lost one of the two mutations* E484Q and become B.1.617.2, which has more cases in UK than the original.

(*B.1.617 has ~13 mutations in fact; only L452R & E484Q received attention)

1/4
Total cases of “double mutant” B.1.617 in the UK is only 193, while its new “single version” B.1.617.2 already has 202 cases.

Losing the E474Q mutation (and ‘becoming single’) must’ve seemed a good thing for the virus.

2/4

health.economictimes.indiatimes.com/news/industry/…
Only B.1.617.1 and B.1.617. 3 have the E484Q mutation, while B.1.617.2 dies not.

Please note that E484Q isn’t the same as E484K, the latter has known immune escape properties.

3/4
Read 4 tweets
4 May
Evidence based medicine is not being practised enough in India. Many "official COVID19 treatments" in India have already been discarded by the world, but patients still receive long lists of drugs that only add to cost & side effects.

1/10
scroll.in/article/993859… via @scroll_in
Chloroquine, Ivermectin, plasma, steam inhalation, 'coronil', azithromycin, doxycycline, oseltamivir, vitamin D (for people without proven deficiency), Zinc, vitamin C, PP inhibitors are still prescribed in India, despite lack of evidence. This is called polypharmacy.

2/10
"There is no harm in giving it" is not a scientific explanation that can justify irrational use. Besides, all harms need not be obvious to the prescriber.

Doctors are trained to use the minimum number, dose & duration of medication for any disease, and only if necessary.

3/10
Read 11 tweets
2 May
Did elections contribute to the COVID-19 surge? We are always tempted to say yes. I decided to do a comparison. Surprisingly, the graphs I obtained from election & non election states are near-identical. This suggests that the wave is a seasonal surge in a geographic region.
1/9
The two images represent election states (where big outdoor gatherings occurred) on the right, and comparable non election states on the left. I have included two sets of pictures. The names of the states are on the graph. If you compare the timelines, it is near-identical.

2/9
The question is whether the surge would have occurred anyway, by pattern, and maybe the large election rallies amplified it to an extent.

This virus behaves in a wave-like pattern in most nations. The reason for the steep upward slope is exponential increase.

3/9
Read 11 tweets
2 May
T cells work against variants & are not affected by E484K or N501Y mutation.

1 dose of vaccine is enough if past infection: the response was so amplified, it even covered the major variants B.1.351 & B.1.1.7. Note that vaccine is based on old virus.

1/5
science.sciencemag.org/content/early/…
But in naive patients, T cell response was lower with one dose of vaccine.

96% (22/23) of vaccinated post infection individuals made a T cell response to Spike protein, compared to 70% (16/23) of vaccinated naïve individuals.

2/5
After 1 dose, vaccination-naïve (no past infection) group attained similar antibody titers to the post infection group at 16–18 & 28–30 weeks.

The majority of SARS-CoV-2 immune naïve individuals made no nAb response to the B.1.1.7 (18/20) and B.1.351 (17/20) after 1 dose.

3/5
Read 5 tweets
2 May
“It is time for India’s policymakers to trust those with relevant expertise, to make sure the necessary data are collected and available, and to accept the value of scientific findings, even if they do not fit the government narrative”

writes @tvpadma

nature.com/articles/d4158…
One such warning we had made in January, based on experience, science and local data.
m.timesofindia.com/india/coronavi…
This warning was reported by The Hindu in January.

“Do not lower guard yet” read the headline.

thehindu.com/news/national/…
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!